These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 22740215)
21. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience. Papadimitrakopoulou VA; Dimery IW; Lee JJ; Perez C; Hong WK; Lippman SM Cancer J Sci Am; 1997; 3(2):92-9. PubMed ID: 9099459 [TBL] [Abstract][Full Text] [Related]
22. [Neoadjuvant chemotherapy for locally advanced gastric cancer]. Kalmár K; Cseke L; Káposztás Z; Horváth G; Varga E Magy Seb; 2003 Oct; 56(5):177-84. PubMed ID: 15022621 [TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929 [TBL] [Abstract][Full Text] [Related]
24. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274 [TBL] [Abstract][Full Text] [Related]
25. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study. Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046 [TBL] [Abstract][Full Text] [Related]
26. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256 [TBL] [Abstract][Full Text] [Related]
27. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer? Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S J BUON; 2009; 14(2):203-9. PubMed ID: 19650167 [TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB. Kim R; Osaki A; Tanabe K; Toge T Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565 [TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma. Finnegan V; Parsons JT; Greene BD; Sharma V Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443 [TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Swain SM; Sorace RA; Bagley CS; Danforth DN; Bader J; Wesley MN; Steinberg SM; Lippman ME Cancer Res; 1987 Jul; 47(14):3889-94. PubMed ID: 3036348 [TBL] [Abstract][Full Text] [Related]
31. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy. Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611 [TBL] [Abstract][Full Text] [Related]
32. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients]. Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471 [TBL] [Abstract][Full Text] [Related]
33. DNA content and tumor response to induction chemotherapy in patients with advanced laryngeal squamous cell carcinoma. Gregg CM; Beals TE; McClatchy KM; Fisher SG; Wolf GT Otolaryngol Head Neck Surg; 1993 Jun; 108(6):731-7. PubMed ID: 8516011 [TBL] [Abstract][Full Text] [Related]
34. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. Holsinger FC; Kies MS; Diaz EM; Gillenwater AM; Lewin JS; Ginsberg LE; Glisson BS; Garden AS; Ark N; Lin HY; Lee JJ; El-Naggar AK; Ki Hong W; Shin DM; Khuri FR J Clin Oncol; 2009 Apr; 27(12):1976-82. PubMed ID: 19289628 [TBL] [Abstract][Full Text] [Related]
35. Changes in laryngeal preservation study help increase accrual. Oncology (Williston Park); 1995 Nov; 9(11):1220. PubMed ID: 8703691 [No Abstract] [Full Text] [Related]
36. Clinical and pathological response to induction chemotherapy used as a prognostic factor in inflammatory breast cancer. Single institution experience. Kolarevic D; Tomasevic Z; Dzodic R; Gavrilovic D; Zegarac M J BUON; 2012; 17(1):21-6. PubMed ID: 22517688 [TBL] [Abstract][Full Text] [Related]
38. Results of an organ preservation protocol with induction chemotherapy and radiotherapy in patients with locally advanced pyriform sinus carcinoma. León X; Quer M; Orús C; Morán J; Recher K Eur Arch Otorhinolaryngol; 2002 Jan; 259(1):32-6. PubMed ID: 11954923 [TBL] [Abstract][Full Text] [Related]
39. [Neoajuvant polychemotherapy at the complex treatment of the patients with laryngeal cancer]. Amiraliev NM Antibiot Khimioter; 2002; 47(3):22-5. PubMed ID: 16127903 [TBL] [Abstract][Full Text] [Related]
40. Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis. Theodoro TR; de Matos LL; Sant Anna AV; Fonseca FL; Semedo P; Martins LC; Nader HB; Del Giglio A; da Silva Pinhal MA Neoplasia; 2007 Jun; 9(6):504-10. PubMed ID: 17603633 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]